Rhythm Pharmaceuticals, Inc.
US ˙ NasdaqGM ˙ US76243J1051

SecurityRYTM / Rhythm Pharmaceuticals, Inc.
InstitutionSei Investments Co
Latest Disclosed Ownership37,432 shares
Latest Disclosed Value $ 4,006,911
Sei Investments Co reports 18.24% increase in ownership of RYTM / Rhythm Pharmaceuticals, Inc.

On February 13, 2026 - Sei Investments Co filed a 13F-HR form disclosing ownership of 37,432 shares of Rhythm Pharmaceuticals, Inc. (US:RYTM) valued at $4,006,721 USD as of December 31, 2025. The entity filed a previous 13F-HR on November 13, 2025 disclosing 31,658 shares of Rhythm Pharmaceuticals, Inc.. This represents a change in shares of 18.24% during the quarter. The current value of the position is $3,170,865 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-02-13 2025-12-31 13F RHYTHM PHARMACEUTICALS COM 76243J105 37,432 5,774 18.24 4,007 25.30 0.0040
2025-11-13 2025-09-30 13F RHYTHM PHARMACEUTICALS COM 76243J105 31,658 -1,487 -4.49 3,197 52.67 0.0034
2025-08-14 2025-06-30 13F RHYTHM PHARMACEUTICALS COM 76243J105 33,145 764 2.36 2,095 22.10 0.0024
2025-05-14 2025-03-31 13F/A-1 RHYTHM PHARMACEUTICALS COM 76243J105 32,381 -1,141 -3.40 1,715 -8.58 0.0022
2025-05-13 2025-03-31 13F RHYTHM PHARMACEUTICALS COM 76243J105 30,141 -3,381 1,667 0.0018
2025-02-11 2024-12-31 13F RHYTHM PHARMACEUTICALS COM 76243J105 33,522 4,501 15.51 1,877 23.42 0.0024
2024-11-12 2024-09-30 13F RHYTHM PHARMACEUTICALS COM 76243J105 29,021 21,651 293.77 1,520 403.31 0.0020
2024-08-13 2024-06-30 13F RHYTHM PHARMACEUTICALS COM 76243J105 7,370 -4,100 -35.75 303 -39.11 0.0004
2024-05-07 2024-03-31 13F RHYTHM PHARMACEUTICALS COM 76243J105 11,470 5,296 85.78 497 75.27 0.0007
2024-02-14 2023-12-31 13F RHYTHM PHARMACEUTICALS COM 76243J105 6,174 6,174 284 0.0005
2023-05-12 2023-03-31 13F RHYTHM PHARMACEUTICALS COM 76243J105 0 -15,453 -100.00 0 -100.00
2023-02-10 2022-12-31 13F RHYTHM PHARMACEUTICALS COM 76243J105 15,453 -3,805 -19.76 450 -4.87 0.0010
2022-11-14 2022-09-30 13F RHYTHM PHARMACEUTICALS COM 76243J105 19,258 19,258 472 0.0011
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.